Relevant bibliographies by topics / Malaghan Institute for Medical Research

Academic literature on the topic 'Malaghan Institute for Medical Research'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Malaghan Institute for Medical Research.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Malaghan Institute for Medical Research"

1

Fischer, Kirsten, Othman Al-Sawaf, Anna-Maria Fink, Mark Dixon, Jasmin Bahlo, Simon Warburton, Thomas J. Kipps, et al. "Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)." Blood 128, no. 22 (December 2, 2016): 2054. http://dx.doi.org/10.1182/blood.v128.22.2054.2054.

Full text
Abstract:
Abstract Introduction The BCL-2 inhibitor venetoclax has yielded promising results in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), both as monotherapy and in combination with rituximab. The CLL14 trial is a prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of obinutuzumab and venetoclax with obinutuzumab and chlorambucil in patients with previously untreated CLL and coexisting medical conditions. Prior to opening the randomized phase, a run-in phase was performed to assess the tolerability of obinutuzumab and venetoclax in this particular patient population. Here, we report the final results on safety and efficacy of this run-in phase. Method The protocol specified to enroll 12 previously untreated patients with confirmed CLL and with coexisting medical conditions assessed by cumulative illness rating scale (CIRS) total score > 6 and/or estimated creatinine clearance (CrCl) < 70 mL/min requiring treatment according to iwCLL criteria into the run-in phase. All patients received 6 cycles of obinutuzumab and venetoclax followed by 6 additional cycles of venetoclax. Obinutuzumab was administered intravenously with 100 mg on day 1, 900 mg on day 2 (option to deliver 1000 mg on day 1), 1000 mg on day 8 and day 15 of cycle 1 and 1000 mg on day1 for cycles 2-6. A gradual weekly dose ramp-up of venetoclax with 20 mg, 50 mg, 100 mg, 200 mg up to 400 mg was administered starting at day 22 of cycle 1. Risk assessment for tumor lysis syndrome (TLS) based on absolute lymphocyte count and tumor burden was performed before treatment in order to direct prophylactic measures. Study defined stopping criteria for all 12 patients included: one treatment-related death or one grade 4 adverse event related to a clinical tumor lysis syndrome (TLS) despite protocol-specified prophylaxis. Adverse events were graded per the NCI CTCAE v.4 criteria. Final response to treatment including assessment for minimal residual disease (MRD) in peripheral blood by ASO-PCR was assessed per the iwCLL guidelines 3 months after the end of treatment, at month 15. Results Between December 2014 and April 2015, 13 previously untreated patients from Australia, Canada, Germany, New Zealand, United States and Spain were enrolled into the trial. Baseline patient characteristics are summarized in Table 1. The median age was 75 years (range 59 - 88) and 62% of the patients were classified as Binet stage C; 38% of the patients were assessed at medium risk and 62% at high risk for TLS. One patient developed a grade-4 infusion related reaction (IRR) during the first dose of obinutuzumab and was therefore withdrawn from the trial according to the protocol requirements. Eleven of 12 patients completed treatment. One patient discontinued treatment after 6 cycles of obinutuzumab and venetoclax and 2 additional cycles of venetoclax due to patient´s wish. All patients experienced at least one adverse event. The commonest adverse events are summarized in Table 2. No clinical TLS was reported. At month 15, 11 of 12 patients were evaluable for final response assessment. All patients responded to therapy. Complete remissions occurred in 7 of the 12 patients including one complete remission with incomplete bone marrow recovery. Ten of 12 patients had no detectable (<10-4) minimal residual disease (MRD) in peripheral blood and one patient was assessed intermediate (≥10-4<10-2). At month 15, there were no events of disease progression or deaths, translating into an estimated progression-free survival of of 100%. Conclusions The treatment regimen developed for the experimental arm of the CLL14 trial comprising obinutuzumab monotherapy for one cycle followed by venetoclax and obinutuzumab in previously untreated, elderly patients with CLL and coexisting medical conditions appears well tolerated and effective. The target population in this trial consists of elderly patients with clinically meaningful comorbidities in addition to CLL. None of the protocol defined stopping safety criteria for the run-in phase of the trial were met. The treatment induced substantial responses with an unprecedentedly high number of MRD negative responses seen in all but one evaluable patients including those with poor prognostic features. The main phase of the CLL14 trial was opened in August 2015 and completed recruitment in August 2016 after 432 patients had been randomized. Disclosures Fischer: Hoffmann-LaRoche: Other: Travel grants. Al-Sawaf:Gilead: Other: Travel grants. Fink:AbbVie: Other: Travel grants; Mundipharma: Other: Travel grants; Celgene: Other: Travel grants, Research Funding; Hoffmann-LaRoche: Other: Travel grants. Dixon:Roche Products Limited: Employment, Equity Ownership. Bahlo:F. Hoffman-La Roche: Honoraria, Other: Travel grant. Warburton:Roche UK: Employment. Kipps:Gilead: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Honoraria. Weinkove:Avalia Immunotherapies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Other: Travel grants; Janssen: Honoraria; Capital & Coast District Health Board: Employment; Malaghan Institute of Medical Research: Employment; Health Research Council of New Zealand: Research Funding; Australasian Leukaemia & Lymphoma Group: Membership on an entity's Board of Directors or advisory committees. Robinson:Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Abbvie: Consultancy; Lundbeck: Consultancy; Gilead: Consultancy. Dreyling:Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau. Opat:Roche: Consultancy, Honoraria, Other: Provision of subsidised drugs, Research Funding. Owen:Pharmacyclics: Research Funding; Janssen: Honoraria; Gilead: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Abbvie: Honoraria; Lundbeck: Honoraria, Research Funding; Novartis: Honoraria. López:Novartis: Consultancy; Abbvie: Consultancy; Merck Sharp & Dohme: Consultancy; Janssen: Consultancy; Roche: Consultancy; Gilead: Consultancy. Humphrey:Genentech, Inc.: Employment. Humerickhouse:AbbVie: Employment. Tausch:Amgen: Other: Travel support; Gilead: Other: Travel support, Speakers Bureau; Celgene: Other: Travel support. Eichhorst:Abbvie: Consultancy; Mundipharma: Consultancy, Research Funding, Speakers Bureau; Roche: Consultancy, Research Funding, Speakers Bureau. Wendtner:Genetech: Consultancy, Honoraria, Research Funding; Hoffmann‐La Roche: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Munipharma: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Janssen‐Cilag: Consultancy, Honoraria, Research Funding; Servier: Consultancy, Honoraria, Research Funding. Langerak:F. Hofmann-LaRoche, Genentech: Research Funding; InVivoScribe Technologies: Patents & Royalties: Royalties are provided to European Network (EuroClonality). Ritgen:Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding. Boettcher:Roche: Research Funding; Abbvie: Research Funding; Celgene: Research Funding. Stilgenbauer:Mundipharma: Consultancy, Honoraria, Other: Travel grants , Research Funding; Novartis: Consultancy, Honoraria, Other: Travel grants , Research Funding; Sanofi: Consultancy, Honoraria, Other: Travel grants , Research Funding; Boehringer Ingelheim: Consultancy, Honoraria, Other: Travel grants , Research Funding; Janssen: Consultancy, Honoraria, Other: Travel grants , Research Funding; Pharmacyclics: Consultancy, Honoraria, Other: Travel grants , Research Funding; Celgene: Consultancy, Honoraria, Other: Travel grants , Research Funding; GSK: Consultancy, Honoraria, Other: Travel grants , Research Funding; Amgen: Consultancy, Honoraria, Other: Travel grants, Research Funding; Genentech: Consultancy, Honoraria, Other: Travel grants , Research Funding; AbbVie: Consultancy, Honoraria, Other: Travel grants, Research Funding; Gilead: Consultancy, Honoraria, Other: Travel grants , Research Funding; Genzyme: Consultancy, Honoraria, Other: Travel grants , Research Funding; Hoffmann-La Roche: Consultancy, Honoraria, Other: Travel grants , Research Funding. Goede:Roche: Consultancy, Honoraria, Other: Travel grant, Research Funding; GlaxoSmithKline: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Mobasher:Genentech, Inc.: Employment. Hallek:Janssen-Cilag: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; AbbVie: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; Mundipharma: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; F. Hoffmann-LaRoche: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; Gilead: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau.
APA, Harvard, Vancouver, ISO, and other styles
2

Andrew, R. R. "The Baker Medical Research Institute." Medical Journal of Australia 143, no. 7 (September 1985): 275–76. http://dx.doi.org/10.5694/j.1326-5377.1985.tb123003.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Korner, Paul I. "The Baker Medical Research Institute." Medical Journal of Australia 143, no. 7 (September 1985): 294–99. http://dx.doi.org/10.5694/j.1326-5377.1985.tb123012.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kato, Atsushi. "Kenya Medical Research Institute, KEMRI." Journal of African Studies 1990, no. 36 (1990): 93–94. http://dx.doi.org/10.11619/africa1964.1990.93.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Steele, Fintan R. "A new medical research institute." Nature Medicine 2, no. 8 (August 1996): 842. http://dx.doi.org/10.1038/nm0896-842a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Powell, Lawrie W. "The Queensland Institute of Medical Research." Medical Journal of Australia 165, no. 11-12 (December 1996): 645–48. http://dx.doi.org/10.5694/j.1326-5377.1996.tb138675.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shine, John. "The Garvan Institute of Medical Research." Medical Journal of Australia 165, no. 11-12 (December 1996): 649–51. http://dx.doi.org/10.5694/j.1326-5377.1996.tb138676.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kidson, Chev. "The Queensland Institute of Medical Research." Medical Journal of Australia 142, no. 6 (March 1985): 355–59. http://dx.doi.org/10.5694/j.1326-5377.1985.tb113415.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nelson, David S. "The Kolling Institute of Medical Research." Medical Journal of Australia 143, no. 3 (August 1985): 97–101. http://dx.doi.org/10.5694/j.1326-5377.1985.tb122831.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Burnet, Macfarlane. "Medical research: the new Hall Institute." Medical Journal of Australia 143, no. 4 (August 1985): 138. http://dx.doi.org/10.5694/j.1326-5377.1985.tb122868.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Malaghan Institute for Medical Research"

1

Erdey, Nancy Carol. "Armor of patience : the National Cancer Institute and the development of medical research policy in the United States, 1937-1971 /." Diss., Case Western Reserve University School of Graduate Studies / OhioLINK, 1995. http://www.ohiolink.edu/etd/view.cgi?acc%5Fnum=case1058363714.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Huan, Xiang Quan. "Depot cytokines and chemokines for antitumor therapy in a mouse model /." [St. Lucia, Qld.], 2004. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe18435.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Anraku, Itaru. "Induction of long lasting protective CD8+ T lymphocyte responses by Kunjin replicon-based vaccine vectors /." [St. Lucia, Qld.], 2005. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe18960.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ye, Mao. "Project management for quality control research of traditional Chinese medicine based on technological innovation." Thesis, University of Macau, 2008. http://umaclib3.umac.mo/record=b2159438.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Senate, University of Arizona Faculty. "Faculty Senate Minutes January 27, 2014." University of Arizona Faculty Senate (Tucson, AZ), 2014. http://hdl.handle.net/10150/312203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vice, President Research Office of the. "Newswire." Office of the Vice President Research, The University of British Columbia, 2008. http://hdl.handle.net/2429/2661.

Full text
Abstract:
UBC's research community recently received a significant boost in financial support for five research hubs that will join the Centre for Brain Health as newly appointed national Centres of Excellence for Commercialization and Research (CECR). Two UBC economics professors were recognized with separate Bank of Canada awards: the Research Fellowship 2008 and the Governor's Award. UBC's Brain Research Centre has recevied $25 million from the Province of BC to establish a new facility focused on translational brain research.
APA, Harvard, Vancouver, ISO, and other styles
7

Tseng, Wen Chih, and 曾文智. "Research on Clinical Genetic Test -- Test Institute, Professional, and Medical device." Thesis, 2005. http://ndltd.ncl.edu.tw/handle/94717460328057329220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Du, Plessis Louis Stephen. "The design of a new Cancer Research Institute and Laboratories for Durban." Thesis, 2008. http://hdl.handle.net/10413/2334.

Full text
Abstract:
Medical research is not only a necessary part in the quest to improve the quality of life for people by finding new diagnostic procedures and treatment; it is also a multi billion rand endeavour. Africa itself poses a huge challenge in providing facilities to respond to the global network engaged in medical research. South Africa has responded in part to this need, and is a pioneer in medical research for the continent. In essence, the continent not only provides great challenges, but also great opportunities for research. Many of its facilities engage in collaborative research with global institutions, but these established ties do not adequately fulfil the capacity required. In addition to this, the research environment is constantly evolving. Not only is the process constantly changing, but also the environments in which the research is conducted and the attitude as to how research should be conducted. To stay as current in the field of medical research, new institutions need to respond to the technical, practical and philosophical changes in the field. The National Health Laboratory Services, a South African chapter 21 institution involved in research and diagnosis, is the proposed client for the cancer research institute to be designed. It has established research credentials in cancer; pioneering the national cancer register; and has established links to other national organisations, such as the Medical Research Council of South Africa.
Thesis (M.Arch.)-University of KwaZulu-Natal, Durban, 2008.
APA, Harvard, Vancouver, ISO, and other styles
9

Friedlander, Tim. "The role of osteopaths in the recognition of melanoma : attitudes, knowledge and practices in melanoma screening within the osteopathic community. A research project submitted in partial requirement for the degree of Master of Osteopathy, UNITEC Institute of Technology [i.e. Unitec New Zealand] /." Diss., 2008. http://www.coda.ac.nz/cgi/viewcontent.cgi?article=1017&context=unitec_hs_di.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Severns, Christopher Ray. "A comparison of geocoding baselayers for electronic medical record data analysis." Thesis, 2014. http://hdl.handle.net/1805/3841.

Full text
Abstract:
Indiana University-Purdue University Indianapolis (IUPUI)
Identifying spatial and temporal patterns of disease occurrence by mapping the residential locations of affected people can provide information that informs response by public health practitioners and improves understanding in epidemiological research. A common method of locating patients at the individual level is geocoding residential addresses stored in electronic medical records (EMRs) using address matching procedures in a geographic information system (GIS). While the process of geocoding is becoming more common in public health studies, few researchers take the time to examine the effects of using different address databases on match rate and positional accuracy of the geocoded results. This research examined and compared accuracy and match rate resulting from four commonly-used geocoding databases applied to sample of 59,341 subjects residing in and around Marion County/ Indianapolis, IN. The results are intended to inform researchers on the benefits and downsides to their selection of a database to geocode patient addresses in EMRs.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Malaghan Institute for Medical Research"

1

The National Institute of General Medical Sciences. [Bethesda, Md.]: National Institutes of Health, National Institute of General Medical Sciences, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

National Institute of General Medical Sciences (U.S.). Annual report : National Institute of General Medical Sciences. [Bethesda, Md.]: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health., 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Diseases, U. S. Army Medical Research Institute of Infectious. United States Army Medical Research Institute of Infectious Diseases. Frederick, MD: USAMRIID, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

The Howard Hughes Medical Institute: A twentieth century history. Chevy Chase, Md: Howard Hughes Medical Institute, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

(India), Institute for Research in Medical Statistics. Institute for Research in Medical Statistics, Indian Council of Medical Research: Silver jubilee : highlights of achievements. New Delhi: Institute for Research in Medical Statistics, Indian Council of Medical Research, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

(India), Institute for Research in Medical Statistics. Institute for Research in Medical Statistics, Indian Council of Medical Research: Silver jubilee : highlights of achievements. New Delhi: Institute for Research in Medical Statistics, Indian Council of Medical Research, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Buscher, Leo F. National Cancer Institute grants process. [Bethesda, Md.?]: National Cancer Institute, U.S. Dept. of Health and Human Services, National Institutes of Health, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Noguchi Memorial Institute for Medical Research. Noguchi Memorial Institute for Medical Research, 2000+: (established 1979) : University of Ghana, Legon. [Legon, Accra, Ghana]: The Institute, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Coriell Institute for Medical Research (U.S.), ed. Coriell: The Coriell Institute of Medical Research and a half century of science. Canton, MA: Science History Publications, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Buscher, Leo F. National Cancer Institute grants process and administration. [Bethesda, Md.?]: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Malaghan Institute for Medical Research"

1

Elliott, Denielle. "The Kenya Medical Research Institute." In Reimagining Science and Statecraft in Postcolonial Kenya, 94–108. New York : Routledge, 2018. | Series: Routledge contemporary Africa series: Routledge, 2018. http://dx.doi.org/10.4324/9781315163840-15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Medawar, P. B. "Animal Experimentation in a Medical Research Institute 1." In The Hope of Progress, 77–86. London: Routledge, 2021. http://dx.doi.org/10.4324/9781003221616-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bokros, Jack. "Medical Carbon Research Institute LLC/On-X Life Technologies Inc." In Heart of Carbon, 137–40. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-17933-4_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Haschke, Ferdinand, and Petra Klassen-Wigger. "Sustainable Clinical Research, Health Economic Aspects and Medical Marketing: Drivers of Product Innovation." In Nestlé Nutrition Institute Workshop Series: Pediatric Program, 125–41. Basel: KARGER, 2010. http://dx.doi.org/10.1159/000318953.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cao, Zhiying. "Research on Medical Information Processing Based on Data Mining Technology." In Lecture Notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering, 510–16. Cham: Springer Nature Switzerland, 2022. http://dx.doi.org/10.1007/978-3-031-18123-8_39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wang, Yixin, Weiqing Fang, Wei Zhu, and Jinshun Ding. "Research on Multi-agency Data Fusion Mode Under Regional Medical Integration." In Lecture Notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering, 267–77. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-82565-2_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wang, Xiao-yan, Guo-hui Wei, Zheng-wei Gu, Jin-gang Ma, Ming Li, and Hui Cao. "Research on Scale Space Fusion Method of Medical Big Data Video Image." In Lecture Notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering, 394–402. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-51100-5_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chu, Wan-Loy, Eng-Lai Tan, Stephen Ambu, Chee-Onn Leong, Vishna Devi Nadarajah, Patricia Kim-Chooi Lim, Shew-Fung Wong, Geok-Lin Khor, James Michael Menke, and Joon-Wah Mak. "Institute for Research, Development and Innovation (IRDI) of the International Medical University (IMU), Malaysia." In The Malaysia-Japan Model on Technology Partnership, 387–95. Tokyo: Springer Japan, 2014. http://dx.doi.org/10.1007/978-4-431-54439-5_39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Grace, Delia, Silvia Alonso, Bernard Bett, Elizabeth Cook, Hu Suk Lee, Anne Liljander, Jeff Mariner, et al. "Zoonoses." In The impact of the International Livestock Research Institute, 302–37. Wallingford: CABI, 2020. http://dx.doi.org/10.1079/9781789241853.0302.

Full text
Abstract:
Abstract This book chapter focuses on zoonoses that are not transmitted primarily through food. Establishing systematic data collection is the first step to manage zoonoses. Management is complicated by heterogeneity: zoonoses may have a significant and debilitating effect on some communities but not on others. Understanding the spatial distribution of the burden of zoonoses is important to better focus control efforts. A significant constraint is the lack of collaboration between medical and veterinary authorities: institutionally speaking, zoonoses typically find themselves homeless and ignored. There is a need for one-health thinking and research to overcome inter-sectoral barriers to effective control of zoonoses.
APA, Harvard, Vancouver, ISO, and other styles
10

Battegazzorre, Edoardo, Andrea Bottino, and Fabrizio Lamberti. "Training Medical Communication Skills with Virtual Patients: Literature Review and Directions for Future Research." In Lecture Notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering, 207–26. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-76426-5_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Malaghan Institute for Medical Research"

1

Lamuri, Aly, Randy Sarayar, Jonathan Purba, and Adrian Sudirman. "Graph Database on Medical Research Data for Integrated Life Science Research." In The annual International Conference and Exhibition on Indonesian Medical Education and Research Institute. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009387000050011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Argentini, M., J. Arkuszewski, John F. Crawford, B. Larsson, Jiri Stepanek, Sarah Teichmann, and R. Weinreich. "Boron neutron capture therapy at the Institute of Medical Radiobiology (IMR) and Paul Scherrer Institute (PSI)." In Fifth International Conference on Applications of Nuclear Techniques: Neutrons in Research and Industry, edited by George Vourvopoulos. SPIE, 1997. http://dx.doi.org/10.1117/12.267843.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stres, Spela. "A cyclotron project for medical and research usage at Jožef Stefan Institute." In 2008 IEEE Nuclear Science Symposium and Medical Imaging conference (2008 NSS/MIC). IEEE, 2008. http://dx.doi.org/10.1109/nssmic.2008.4775004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Siswanto, Putri, and Riries Rulaningtyas. "Artificial Neural Network and Its Application in Medical Disease Prediction: Review Article." In The annual International Conference and Exhibition on Indonesian Medical Education and Research Institute. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009387400170025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nuranna, Laila, Gatot Purwoto, Annisa Sukana, and Alexander Peter. "TeleDoVIA Meeting the Challenge of Early Detection on Cervical Cancer: A Pilot Study in Indonesia." In The annual International Conference and Exhibition on Indonesian Medical Education and Research Institute. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009387200120016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Aditianingsih, Dita, Besthadi Sukmono, Erika Adiwongso, and Chaidir Mochtar. "Effect of Pre-incisional Ultrasound-guided Quadratus Lumborum Block on Perioperative Analgesia and Inflammatory Responses in Transperitoneal Laparoscopic Nephrectomy: A Single-blinded, Randomised Control Trial." In The annual International Conference and Exhibition on Indonesian Medical Education and Research Institute. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009387900260032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sipa, Donni Maulana, and Jamrud Aminuddin. "Determination of Thorax Exposure Factors in Conventional X-rays Imaging using the Artificial Neural Network Method." In The annual International Conference and Exhibition on Indonesian Medical Education and Research Institute. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009388100330037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nugraha, Krishna, M. Fadlan, Dea Kurniawan, Liemena Adrian, Faris Nugroho, Puspa Lestari, Seprian Widasmara, Anita Santoso, and Mohammad Rohman. "The Symptoms-based Algorithm for Early Detection of Systolic Heart Failure." In The annual International Conference and Exhibition on Indonesian Medical Education and Research Institute. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009388300380041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Santoso, Anita Surya, Krishna Ari Nugraha, M. Rizki Fadlan, Dea Arie Kurniawan, Liemena Harold Adrian, Faris Wahyu Nugroho, Puspa Lestari, Seprian Widasmara, and Mohammad Saifur Rohman. "Saiful Anwar Hospital Heart Failure Registry (SAHEFAR): A Valuable Tool for Improving the Management of Patients with Heart Failure in Malang, East Java." In The annual International Conference and Exhibition on Indonesian Medical Education and Research Institute. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009388400420047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pramudya, Astrid, Mohammad Rohman, Muhamad Fadlan, Liemena Adrian, Faris Nugroho, Monika Sitio, Diah Ivanasari, and Ardani Prakosa. "Increasing Health Care Provider Awareness on Cardiovascular Disease by Malang Cardiovascular Networking System." In The annual International Conference and Exhibition on Indonesian Medical Education and Research Institute. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009388500480052.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Malaghan Institute for Medical Research"

1

NAVAL MEDICAL RESEARCH INST BETHESDA MD. Summaries of Research 1992 (Naval Medical Research Institute). Fort Belvoir, VA: Defense Technical Information Center, January 1992. http://dx.doi.org/10.21236/ada275367.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Alcaide, C., A. O. Anderson, C. L. Bailey, K. Baksi, and M. A. Balady. U.S. Army Medical Research Institute of Infectious Diseases Annual Report, Fiscal Year 1986. Fort Belvoir, VA: Defense Technical Information Center, October 1986. http://dx.doi.org/10.21236/ada230324.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Amano, K. I., A. O. Anderson, C. L. Bailey, M. Balady, and R. F. Berendt. U.S. Army Medical Research Institute of Infectious Disease Annual Progress Report, Fiscal Year 1985. Fort Belvoir, VA: Defense Technical Information Center, October 1985. http://dx.doi.org/10.21236/ada230449.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Moore, Melissa. Phase II - Procurement of State of the Art Research Equipment to Support Faculty Members with the RNA Therapeutics Institute, a component of the Advanced Therapeutics Cluster at the University of Massachusetts Medical School. Office of Scientific and Technical Information (OSTI), October 2011. http://dx.doi.org/10.2172/1037882.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jones, Nicole S., Jeri D. Ropero-Miller, Heather Waltke, Danielle McLeod-Henning, Danielle Weiss, and Hannah Barcus. Proceedings of the International Forensic Radiology Research Summit May 10–11, 2016, Amsterdam, The Netherlands. RTI Press, September 2017. http://dx.doi.org/10.3768/rtipress.2017.cp.0005.1709.

Full text
Abstract:
On May 10–11, 2016, the US Department of Justice (DOJ) National Institute of Justice (NIJ), the Netherlands Forensic Institute (NFI; Dutch Ministry of Security and Justice of the Netherlands), the International Society for Forensic Radiology and Imaging (ISFRI), the International Association of Forensic Radiographers (IAFR), and NIJ’s Forensic Technology Center of Excellence (FTCoE) at RTI International organized and convened the International Forensic Radiology Research Summit (IFRRS) at the Academic Medical Center in Amsterdam. The summit assembled 40 international subject matter experts in forensic radiology, to include researchers, practitioners, government employees, and professional staff from 14 countries. The goal of this 2-day summit was to identify gaps, challenges, and research needs to produce a road map to success regarding the state of forensic radiology, including formulating a plan to address the obstacles to implementation of advanced imaging technologies in medicolegal investigations. These proceedings summarize the meeting’s important exchange of technical and operational information, ideas, and solutions for the community and other stakeholders of forensic radiology.
APA, Harvard, Vancouver, ISO, and other styles
6

Norsworthy, Sarah, Rebecca Shute, Crystal M. Daye, and Paige Presler-Jur. National Institute of Justice’s Forensic Technology Center of Excellence 2019 National Opioid and Emerging Drug Threats Policy and Practice Forum. Edited by Jeri D. Ropero-Miller and Hope Smiley-McDonald. RTI Press, July 2020. http://dx.doi.org/10.3768/rtipress.2020.cp.0011.2007.

Full text
Abstract:
The National Institute of Justice (NIJ) and its Forensic Technology Center of Excellence (FTCoE) hosted the National Opioid and Emerging Drug Threats Policy and Practice Forum on July 18–19, 2019, in Washington, DC. The forum explored ways in which government agencies and programs, law enforcement officials, forensic laboratory personnel, medical examiners and coroners, researchers, and other experts can cooperate to respond to problems associated with drug abuse and misuse. Panelists from these stakeholder groups discussed ways to address concerns such as rapidly expanding crime laboratory caseloads; workforce shortages and resiliency programs; analytical challenges associated with fentanyl analogs and drug mixtures; laboratory quality control; surveillance systems to inform response; and policy related to stakeholder, research, and resource constraints. The NIJ Policy and Practice Forum built off the momentum of previous stakeholder meetings convened by NIJ and other agencies to discuss the consequences of this national epidemic, including the impact it has had on public safety, public health, and the criminal justice response. The forum discussed topics at a policy level and addressed best practices used across the forensic community.
APA, Harvard, Vancouver, ISO, and other styles
7

Rankin, Nicole, Deborah McGregor, Candice Donnelly, Bethany Van Dort, Richard De Abreu Lourenco, Anne Cust, and Emily Stone. Lung cancer screening using low-dose computed tomography for high risk populations: Investigating effectiveness and screening program implementation considerations: An Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the Cancer Institute NSW. The Sax Institute, October 2019. http://dx.doi.org/10.57022/clzt5093.

Full text
Abstract:
Background Lung cancer is the number one cause of cancer death worldwide.(1) It is the fifth most commonly diagnosed cancer in Australia (12,741 cases diagnosed in 2018) and the leading cause of cancer death.(2) The number of years of potential life lost to lung cancer in Australia is estimated to be 58,450, similar to that of colorectal and breast cancer combined.(3) While tobacco control strategies are most effective for disease prevention in the general population, early detection via low dose computed tomography (LDCT) screening in high-risk populations is a viable option for detecting asymptomatic disease in current (13%) and former (24%) Australian smokers.(4) The purpose of this Evidence Check review is to identify and analyse existing and emerging evidence for LDCT lung cancer screening in high-risk individuals to guide future program and policy planning. Evidence Check questions This review aimed to address the following questions: 1. What is the evidence for the effectiveness of lung cancer screening for higher-risk individuals? 2. What is the evidence of potential harms from lung cancer screening for higher-risk individuals? 3. What are the main components of recent major lung cancer screening programs or trials? 4. What is the cost-effectiveness of lung cancer screening programs (include studies of cost–utility)? Summary of methods The authors searched the peer-reviewed literature across three databases (MEDLINE, PsycINFO and Embase) for existing systematic reviews and original studies published between 1 January 2009 and 8 August 2019. Fifteen systematic reviews (of which 8 were contemporary) and 64 original publications met the inclusion criteria set across the four questions. Key findings Question 1: What is the evidence for the effectiveness of lung cancer screening for higher-risk individuals? There is sufficient evidence from systematic reviews and meta-analyses of combined (pooled) data from screening trials (of high-risk individuals) to indicate that LDCT examination is clinically effective in reducing lung cancer mortality. In 2011, the landmark National Lung Cancer Screening Trial (NLST, a large-scale randomised controlled trial [RCT] conducted in the US) reported a 20% (95% CI 6.8% – 26.7%; P=0.004) relative reduction in mortality among long-term heavy smokers over three rounds of annual screening. High-risk eligibility criteria was defined as people aged 55–74 years with a smoking history of ≥30 pack-years (years in which a smoker has consumed 20-plus cigarettes each day) and, for former smokers, ≥30 pack-years and have quit within the past 15 years.(5) All-cause mortality was reduced by 6.7% (95% CI, 1.2% – 13.6%; P=0.02). Initial data from the second landmark RCT, the NEderlands-Leuvens Longkanker Screenings ONderzoek (known as the NELSON trial), have found an even greater reduction of 26% (95% CI, 9% – 41%) in lung cancer mortality, with full trial results yet to be published.(6, 7) Pooled analyses, including several smaller-scale European LDCT screening trials insufficiently powered in their own right, collectively demonstrate a statistically significant reduction in lung cancer mortality (RR 0.82, 95% CI 0.73–0.91).(8) Despite the reduction in all-cause mortality found in the NLST, pooled analyses of seven trials found no statistically significant difference in all-cause mortality (RR 0.95, 95% CI 0.90–1.00).(8) However, cancer-specific mortality is currently the most relevant outcome in cancer screening trials. These seven trials demonstrated a significantly greater proportion of early stage cancers in LDCT groups compared with controls (RR 2.08, 95% CI 1.43–3.03). Thus, when considering results across mortality outcomes and early stage cancers diagnosed, LDCT screening is considered to be clinically effective. Question 2: What is the evidence of potential harms from lung cancer screening for higher-risk individuals? The harms of LDCT lung cancer screening include false positive tests and the consequences of unnecessary invasive follow-up procedures for conditions that are eventually diagnosed as benign. While LDCT screening leads to an increased frequency of invasive procedures, it does not result in greater mortality soon after an invasive procedure (in trial settings when compared with the control arm).(8) Overdiagnosis, exposure to radiation, psychological distress and an impact on quality of life are other known harms. Systematic review evidence indicates the benefits of LDCT screening are likely to outweigh the harms. The potential harms are likely to be reduced as refinements are made to LDCT screening protocols through: i) the application of risk predication models (e.g. the PLCOm2012), which enable a more accurate selection of the high-risk population through the use of specific criteria (beyond age and smoking history); ii) the use of nodule management algorithms (e.g. Lung-RADS, PanCan), which assist in the diagnostic evaluation of screen-detected nodules and cancers (e.g. more precise volumetric assessment of nodules); and, iii) more judicious selection of patients for invasive procedures. Recent evidence suggests a positive LDCT result may transiently increase psychological distress but does not have long-term adverse effects on psychological distress or health-related quality of life (HRQoL). With regards to smoking cessation, there is no evidence to suggest screening participation invokes a false sense of assurance in smokers, nor a reduction in motivation to quit. The NELSON and Danish trials found no difference in smoking cessation rates between LDCT screening and control groups. Higher net cessation rates, compared with general population, suggest those who participate in screening trials may already be motivated to quit. Question 3: What are the main components of recent major lung cancer screening programs or trials? There are no systematic reviews that capture the main components of recent major lung cancer screening trials and programs. We extracted evidence from original studies and clinical guidance documents and organised this into key groups to form a concise set of components for potential implementation of a national lung cancer screening program in Australia: 1. Identifying the high-risk population: recruitment, eligibility, selection and referral 2. Educating the public, people at high risk and healthcare providers; this includes creating awareness of lung cancer, the benefits and harms of LDCT screening, and shared decision-making 3. Components necessary for health services to deliver a screening program: a. Planning phase: e.g. human resources to coordinate the program, electronic data systems that integrate medical records information and link to an established national registry b. Implementation phase: e.g. human and technological resources required to conduct LDCT examinations, interpretation of reports and communication of results to participants c. Monitoring and evaluation phase: e.g. monitoring outcomes across patients, radiological reporting, compliance with established standards and a quality assurance program 4. Data reporting and research, e.g. audit and feedback to multidisciplinary teams, reporting outcomes to enhance international research into LDCT screening 5. Incorporation of smoking cessation interventions, e.g. specific programs designed for LDCT screening or referral to existing community or hospital-based services that deliver cessation interventions. Most original studies are single-institution evaluations that contain descriptive data about the processes required to establish and implement a high-risk population-based screening program. Across all studies there is a consistent message as to the challenges and complexities of establishing LDCT screening programs to attract people at high risk who will receive the greatest benefits from participation. With regards to smoking cessation, evidence from one systematic review indicates the optimal strategy for incorporating smoking cessation interventions into a LDCT screening program is unclear. There is widespread agreement that LDCT screening attendance presents a ‘teachable moment’ for cessation advice, especially among those people who receive a positive scan result. Smoking cessation is an area of significant research investment; for instance, eight US-based clinical trials are now underway that aim to address how best to design and deliver cessation programs within large-scale LDCT screening programs.(9) Question 4: What is the cost-effectiveness of lung cancer screening programs (include studies of cost–utility)? Assessing the value or cost-effectiveness of LDCT screening involves a complex interplay of factors including data on effectiveness and costs, and institutional context. A key input is data about the effectiveness of potential and current screening programs with respect to case detection, and the likely outcomes of treating those cases sooner (in the presence of LDCT screening) as opposed to later (in the absence of LDCT screening). Evidence about the cost-effectiveness of LDCT screening programs has been summarised in two systematic reviews. We identified a further 13 studies—five modelling studies, one discrete choice experiment and seven articles—that used a variety of methods to assess cost-effectiveness. Three modelling studies indicated LDCT screening was cost-effective in the settings of the US and Europe. Two studies—one from Australia and one from New Zealand—reported LDCT screening would not be cost-effective using NLST-like protocols. We anticipate that, following the full publication of the NELSON trial, cost-effectiveness studies will likely be updated with new data that reduce uncertainty about factors that influence modelling outcomes, including the findings of indeterminate nodules. Gaps in the evidence There is a large and accessible body of evidence as to the effectiveness (Q1) and harms (Q2) of LDCT screening for lung cancer. Nevertheless, there are significant gaps in the evidence about the program components that are required to implement an effective LDCT screening program (Q3). Questions about LDCT screening acceptability and feasibility were not explicitly included in the scope. However, as the evidence is based primarily on US programs and UK pilot studies, the relevance to the local setting requires careful consideration. The Queensland Lung Cancer Screening Study provides feasibility data about clinical aspects of LDCT screening but little about program design. The International Lung Screening Trial is still in the recruitment phase and findings are not yet available for inclusion in this Evidence Check. The Australian Population Based Screening Framework was developed to “inform decision-makers on the key issues to be considered when assessing potential screening programs in Australia”.(10) As the Framework is specific to population-based, rather than high-risk, screening programs, there is a lack of clarity about transferability of criteria. However, the Framework criteria do stipulate that a screening program must be acceptable to “important subgroups such as target participants who are from culturally and linguistically diverse backgrounds, Aboriginal and Torres Strait Islander people, people from disadvantaged groups and people with a disability”.(10) An extensive search of the literature highlighted that there is very little information about the acceptability of LDCT screening to these population groups in Australia. Yet they are part of the high-risk population.(10) There are also considerable gaps in the evidence about the cost-effectiveness of LDCT screening in different settings, including Australia. The evidence base in this area is rapidly evolving and is likely to include new data from the NELSON trial and incorporate data about the costs of targeted- and immuno-therapies as these treatments become more widely available in Australia.
APA, Harvard, Vancouver, ISO, and other styles
8

Lees, Shelley, and Mark Marchant. Key Considerations: Cross-Border Dynamics Between Uganda and Tanzania in the Context of the Outbreak of Ebola, 2022. Institute of Development Studies, December 2022. http://dx.doi.org/10.19088/sshap.2022.046.

Full text
Abstract:
This brief summarises key considerations concerning cross-border dynamics between Tanzania and Uganda in the context of the outbreak of Ebola (Sudan Virus Disease, SVD) in Uganda. It is part of a series focusing on at-risk border areas between Uganda and four high priority neighbouring countries: Rwanda; Tanzania; Kenya and South Sudan. The current outbreak is of the Sudan strain of Ebola (SVD). SVD is used in this paper to refer to the current outbreak in East Africa, whereas outbreaks of Zaire Ebolavirus disease or general references to Ebola are referred to as EVD. The current outbreak began in Mubende, Uganda, on 19 September 2022, approximately 240km from the Uganda-Tanzania border. It has since spread to nine Ugandan districts, including two in the Kampala metropolitan area. Kampala is a transport hub, with a population over 3.6 million. While the global risk from SVD remains low according to the World Health Organization, its presence in the Ugandan capital has significantly heightened the risk to regional neighbours. At the time of writing, there had been no cases of Ebola imported from Uganda into Tanzania. This brief provides details about cross-border relations, the political and economic dynamics likely to influence these, and specific areas and actors most at risk. It is based on a rapid review of existing published and grey literature, previous ethnographic research in Tanzania, and informal discussions with colleagues from the Tanzania’s Ministry of Health, Community Development, Gender, Elderly and Children (MoHCDGEC), Tanzania National Institute for Medical Research (NIMR), Uganda Red Cross Society, Tanzania Red Cross Society (TRCS), International Organization for Migration (IOM), IFRC, US CDC and CDC Tanzania. The brief was developed by Shelley Lees and Mark Marchant (London School of Hygiene & Tropical Medicine) with support from Olivia Tulloch (Anthrologica) and Hugh Lamarque (University of Edinburgh). Additional review and inputs were provided by The Tanzania Red Cross and UNICEF. The brief is the responsibility of the Social Science in Humanitarian Action Platform (SSHAP).
APA, Harvard, Vancouver, ISO, and other styles
9

Smit, Amelia, Kate Dunlop, Nehal Singh, Diona Damian, Kylie Vuong, and Anne Cust. Primary prevention of skin cancer in primary care settings. The Sax Institute, August 2022. http://dx.doi.org/10.57022/qpsm1481.

Full text
Abstract:
Overview Skin cancer prevention is a component of the new Cancer Plan 2022–27, which guides the work of the Cancer Institute NSW. To lessen the impact of skin cancer on the community, the Cancer Institute NSW works closely with the NSW Skin Cancer Prevention Advisory Committee, comprising governmental and non-governmental organisation representatives, to develop and implement the NSW Skin Cancer Prevention Strategy. Primary Health Networks and primary care providers are seen as important stakeholders in this work. To guide improvements in skin cancer prevention and inform the development of the next NSW Skin Cancer Prevention Strategy, an up-to-date review of the evidence on the effectiveness and feasibility of skin cancer prevention activities in primary care is required. A research team led by the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW, was contracted to undertake an Evidence Check review to address the questions below. Evidence Check questions This Evidence Check aimed to address the following questions: Question 1: What skin cancer primary prevention activities can be effectively administered in primary care settings? As part of this, identify the key components of such messages, strategies, programs or initiatives that have been effectively implemented and their feasibility in the NSW/Australian context. Question 2: What are the main barriers and enablers for primary care providers in delivering skin cancer primary prevention activities within their setting? Summary of methods The research team conducted a detailed analysis of the published and grey literature, based on a comprehensive search. We developed the search strategy in consultation with a medical librarian at the University of Sydney and the Cancer Institute NSW team, and implemented it across the databases Embase, MEDLINE, PsycInfo, Scopus, Cochrane Central and CINAHL. Results were exported and uploaded to Covidence for screening and further selection. The search strategy was designed according to the SPIDER tool for Qualitative and Mixed-Methods Evidence Synthesis, which is a systematic strategy for searching qualitative and mixed-methods research studies. The SPIDER tool facilitates rigour in research by defining key elements of non-quantitative research questions. We included peer-reviewed and grey literature that included skin cancer primary prevention strategies/ interventions/ techniques/ programs within primary care settings, e.g. involving general practitioners and primary care nurses. The literature was limited to publications since 2014, and for studies or programs conducted in Australia, the UK, New Zealand, Canada, Ireland, Western Europe and Scandinavia. We also included relevant systematic reviews and evidence syntheses based on a range of international evidence where also relevant to the Australian context. To address Question 1, about the effectiveness of skin cancer prevention activities in primary care settings, we summarised findings from the Evidence Check according to different skin cancer prevention activities. To address Question 2, about the barriers and enablers of skin cancer prevention activities in primary care settings, we summarised findings according to the Consolidated Framework for Implementation Research (CFIR). The CFIR is a framework for identifying important implementation considerations for novel interventions in healthcare settings and provides a practical guide for systematically assessing potential barriers and facilitators in preparation for implementing a new activity or program. We assessed study quality using the National Health and Medical Research Council (NHMRC) levels of evidence. Key findings We identified 25 peer-reviewed journal articles that met the eligibility criteria and we included these in the Evidence Check. Eight of the studies were conducted in Australia, six in the UK, and the others elsewhere (mainly other European countries). In addition, the grey literature search identified four relevant guidelines, 12 education/training resources, two Cancer Care pathways, two position statements, three reports and five other resources that we included in the Evidence Check. Question 1 (related to effectiveness) We categorised the studies into different types of skin cancer prevention activities: behavioural counselling (n=3); risk assessment and delivering risk-tailored information (n=10); new technologies for early detection and accompanying prevention advice (n=4); and education and training programs for general practitioners (GPs) and primary care nurses regarding skin cancer prevention (n=3). There was good evidence that behavioural counselling interventions can result in a small improvement in sun protection behaviours among adults with fair skin types (defined as ivory or pale skin, light hair and eye colour, freckles, or those who sunburn easily), which would include the majority of Australians. It was found that clinicians play an important role in counselling patients about sun-protective behaviours, and recommended tailoring messages to the age and demographics of target groups (e.g. high-risk groups) to have maximal influence on behaviours. Several web-based melanoma risk prediction tools are now available in Australia, mainly designed for health professionals to identify patients’ risk of a new or subsequent primary melanoma and guide discussions with patients about primary prevention and early detection. Intervention studies have demonstrated that use of these melanoma risk prediction tools is feasible and acceptable to participants in primary care settings, and there is some evidence, including from Australian studies, that using these risk prediction tools to tailor primary prevention and early detection messages can improve sun-related behaviours. Some studies examined novel technologies, such as apps, to support early detection through skin examinations, including a very limited focus on the provision of preventive advice. These novel technologies are still largely in the research domain rather than recommended for routine use but provide a potential future opportunity to incorporate more primary prevention tailored advice. There are a number of online short courses available for primary healthcare professionals specifically focusing on skin cancer prevention. Most education and training programs for GPs and primary care nurses in the field of skin cancer focus on treatment and early detection, though some programs have specifically incorporated primary prevention education and training. A notable example is the Dermoscopy for Victorian General Practice Program, in which 93% of participating GPs reported that they had increased preventive information provided to high-risk patients and during skin examinations. Question 2 (related to barriers and enablers) Key enablers of performing skin cancer prevention activities in primary care settings included: • Easy access and availability of guidelines and point-of-care tools and resources • A fit with existing workflows and systems, so there is minimal disruption to flow of care • Easy-to-understand patient information • Using the waiting room for collection of risk assessment information on an electronic device such as an iPad/tablet where possible • Pairing with early detection activities • Sharing of successful programs across jurisdictions. Key barriers to performing skin cancer prevention activities in primary care settings included: • Unclear requirements and lack of confidence (self-efficacy) about prevention counselling • Limited availability of GP services especially in regional and remote areas • Competing demands, low priority, lack of time • Lack of incentives.
APA, Harvard, Vancouver, ISO, and other styles
10

Cancer Research Institute, Loma Linda University Medical Center. Office of Scientific and Technical Information (OSTI), August 1994. http://dx.doi.org/10.2172/50988.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Malaghan Institute for Medical Research' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography